Details of the Drug | DrugMAP

General Information of Drug (ID: DM353WG)

Drug Name

TAP311

Indication

Disease Entry	ICD 11	Status	REF
Dyslipidemia	5C80-5C81	Phase 1	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C34H40F6N6O4
Canonical SMILES: CCC1CC(CC(N1C(=O)OC2CCC(CC2)C(=O)O)CC)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)C5=CN(N=C5)C
InChI: 1S/C34H40F6N6O4/c1-4-26-13-28(14-27(5-2)46(26)32(49)50-29-8-6-21(7-9-29)30(47)48)45(31-41-15-22(16-42-31)23-17-43-44(3)19-23)18-20-10-24(33(35,36)37)12-25(11-20)34(38,39)40/h10-12,15-17,19,21,26-29H,4-9,13-14,18H2,1-3H3,(H,47,48)/t21?,26-,27+,28?,29?
InChIKey: KSPXRTYMEVDHAB-LTZKBQIGSA-N

Cross-matching ID

PubChem CID: 57686716
TTD ID: D08VBV

References

1	ClinicalTrials.gov (NCT01487460) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients. U.S. National Institutes of Health.